Bind aims to price IPO of 4.7 million shares between $14.00 and $16.00

Credit Suisse and Cowen are joint bookrunners; JMP, Stifel to assist

By Devika Patel

Knoxville, Tenn., Sept. 5 - Bind Therapeutics, Inc. will sell 4.7 million common shares in its initial public offering with a 30-day greenshoe for 705,000 additional shares. The deal was announced Aug. 12.

The shares will be sold at a price expected to be between $14.00 and $16.00 per share, according to an S-1/A filing made Thursday with the Securities and Exchange Commission.

Credit Suisse Securities (USA) LLC and Cowen and Co., LLC are the joint bookrunning managers. Stifel, Nicolaus & Co., Inc. and JMP Securities LLC are the co-managers.

Proceeds will be used for development of BIND-014, working capital and general corporate purposes.

Based in Cambridge, Mass., the clinical-stage nanomedicine company is developing Accurins, which is designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease. The company intends to list its common stock on the Nasdaq under the symbol "BIND."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.